Clinical Trials
35 trialsNCT05579366 2026-05-26
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT03564340 2026-05-08
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT05417594 2026-05-05
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT03393884 2026-05-04
OVATION 2
Imunon
Phase 1/2 Active not recruiting
NCT05739981 2026-05-04
MRD
Imunon
Phase 1/2 Recruiting
NCT05985655 2026-04-23
ELUCIDATE
Exscientia AI Limited
Phase 1/2 Recruiting
NCT04657068 2026-03-18
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Phase 1/2 Recruiting
NCT05198804 2026-03-18
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1/2 Completed
NCT07480954 2026-03-18
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT06545617 2026-01-07
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
Bio-Thera Solutions
Phase 1/2 Withdrawn
NCT07322094 2026-01-07
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
TORL Biotherapeutics, LLC
Phase 1/2 Recruiting
NCT04590326 2025-11-21
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03519178 2025-11-14
A Study of PF-06873600 in People With Cancer
Pfizer
Phase 1/2 Terminated
NCT05949632 2025-08-03
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Incyte Corporation
Phase 1/2 Terminated
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06087289 2025-06-08
KANDOVA
Novakand Pharma AB
Phase 1/2 Completed
NCT04442126 2025-05-23
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
Phase 1/2 Terminated
NCT05261490 2024-11-19
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pfizer
Phase 1/2 Terminated
NCT05199272 2024-11-15
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe, Inc.
Phase 1/2 Active not recruiting
NCT03345485 2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2 Completed
NCT05001282 2024-08-07
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Elucida Oncology
Phase 1/2 Terminated
NCT02606305 2024-06-14
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
Phase 1/2 Completed
NCT05538624 2024-04-24
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
Avenge Bio, Inc
Phase 1/2 Terminated
NCT03311334 2024-04-18
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT04814875 2024-02-14
A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy
THERAPIM PTY LTD
Phase 1/2 Terminated
NCT02915523 2024-01-10
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Syndax Pharmaceuticals
Phase 1/2 Completed
NCT01482715 2023-06-09
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
pharmaand GmbH
Phase 1/2 Completed
NCT02759588 2023-01-05
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Genelux Corporation
Phase 1/2 Completed
NCT04042116 2022-12-20
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
Clovis Oncology, Inc.
Phase 1/2 Suspended
NCT02657889 2022-12-01
TOPACIO
Tesaro, Inc.
Phase 1/2 Completed
NCT02785250 2021-06-18
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 1/2 Unknown
NCT01663857 2019-09-11
A Study LY2228820 for Recurrent Ovarian Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT00091377 2016-07-14
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
MEI Pharma, Inc.
Phase 1/2 Completed
NCT00421889 2015-07-28
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
Valerio Therapeutics
Phase 1/2 Completed